The Fly

Chemours upgraded to Buy from Neutral at UBS

UBS analyst Joshua Spector upgraded Chemours to Buy from Neutral with a price target of $43, up from $31. UBS believes TiO2 earnings will recover through 2023 from current trough levels, with focus shifting to sustainability-led growth in non-TiO2 segments, driving EBITDA toward record highs in the firm’s outlook and lifting Chemours’s multiple, the analyst tells investors in a research note.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on CC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More